Clinical Trial Update: A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating oral prolonged-release dalfampridine (BIIB041) for safety and efficacy in Japanese participants with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Dalfampridine (dalfampridine)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis, Remittent Progressive, Multiple Sclerosis, Primary Progressive | Phase 3 | Status: COMPLETED